The UK's life sciences sector has just received a massive boost in confidence, attracting an impressive £3 billion in new public and private investment over the past 12 months. This significant influx of capital is being hailed as international recognition of the UK's cutting-edge scientific innovation and thriving health ecosystem – with direct benefits for patient care and economic growth across the nation.
The investment follows the government's implementation of its Life Sciences Sector Plan, which aims to position the UK as a global leader in life sciences. A notable outcome has been the acceleration of access to transformative new treatments. For example, the world's first immunotherapy for type 1 diabetes recently gained approval for use by the NHS in England and Wales – a practical demonstration of this focused investment. Furthermore, the average waiting time to establish clinical trials has reportedly decreased from 169 to 122 days in the first half of 2025-2026, with a new joint approval process between the MHRA and NICE expected to bring new medicines to patients up to six months sooner.
Major private sector contributions are driving much of this growth. AstraZeneca has committed £300 million to its Cambridge headquarters and a Macclesfield facility, where AI is used for drug discovery. Moderna is establishing a new innovation centre in Harwell with a planned £1 billion UK research and development investment over the next decade, while UCB is investing £500 million in a new R&D hub in Windlesham, Surrey, focusing on immunological diseases. These investments not only fuel innovation but also breathe life into regional economies.
The sector is a significant employer, generating approximately £147 billion in turnover and employing around 360,000 people across the UK. Nearly half of these positions are located outside of London and the South East. A new, dedicated Jobs Plan has been introduced to support this expansion, aiming to unlock the talent required for an additional 66,000 roles in priority occupations within the sector by 2035. These roles span various disciplines, from laboratory technicians and chemical scientists to software developers, ensuring a diverse range of opportunities.
This announcement comes as part of the first annual implementation update on the Life Sciences Sector Plan, which outlines the government's progress towards its overarching goal of making the UK the third-largest life sciences economy globally by 2035. Science, Innovation, and Technology Secretary Liz Kendall highlighted that the plan is delivering cutting-edge treatments, creating opportunities for British businesses, and generating well-paid jobs – benefiting both NHS patients and the wider economy.
Health and Social Care Secretary James Murray added that the £3 billion investment will speed up access to innovative treatments and transform patient experience, crediting success to combining British scientific expertise with global collaboration.